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Objectives: Arthritis with intra-articular inﬂammation was accompanied by joint pain, swelling, and
stiffness leading to signiﬁcant functional impairment. Thus, regulation of joint inﬂammation is a good
therapeutic approach for patients with arthritis. In this study, the effect of low intensity ultrasound
(LIUS) applied to an adjuvant-induced arthritic rat model on the synovium was investigated.
Design: Synovial inﬂammation was induced by complete Freund’s adjuvant (CFA)-injection into the rat
knee joint. LIUS (200 mW/cm2) was applied on the ipsilateral knee everyday for 10 min beginning 1 day
after inﬂammation induction. The expression of proinﬂammatory factors and immunohistochemical
staining pattern of the synovium were assessed.
Results: CFA induced an increase of the knee circumference that was signiﬁcantly diminished by LIUS.
Synovial membrane hyperplasia in the ipsilateral joint was also affected by LIUS. The inﬂammatory
mediators, COX-1/2, IL-1b, and iNOS, but not TNF-a, in the synovial membrane were induced after 3 days,
and they closely correlated with the degree of edema. In the synovial membrane, the expression of
inﬂammatory mediators was reduced by LIUS. The chemoattractant chemokine receptor CCR5 also was
involved. On immunohistochemical analysis, CFA caused increased inﬁltration of CD11b-positive cells in
the synovium. After 3 days, neutrophils, myeloperoxidase (MPO)-positive cells ﬁlled the inﬂammatory
core; later, monocytes and macrophages, ionized calcium binding adaptor molecule 1 (Iba1)-positive
cells in the periphery inﬁltrated the core by day 5. LIUS markedly reduced CFA-induced inﬂammatory
cells inﬁltration.
Conclusion: LIUS showed a potent anti-inﬂammatory effect in this animal arthritis model with reduced
inﬁltration of inﬂammatory cells into the synovium.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Arthritis is characterized by joint inﬂammation, which includes
immune cell inﬁltration, synovial hyperplasia, pain, and swelling1.
The immune cell inﬁltrate plays an important role in the inﬂam-
matory process. First, inﬂamed tissue releases proinﬂammatory
molecules such as cytokines and prostaglandins (PGs) that act as
warning signals. These molecules promote leukocyte inﬁltration
into the inﬂamed tissue through enhanced expression ofto: E.J. Baik, Department of
ncheon-dong, Yeongtong-gu,
42; Fax: 82-31-219-5049.
s Research Society International. Pchemokines and adhesion molecules. The inﬂammatory cells then
produce inﬂammatory mediators such as interleukins (ILs), tumor
necrosis factor alpha (TNF-a), nitric oxide (NO), and prostaglandins
E2 (PGE2), which further aggravate synovial inﬂammation. PGE2 is
a well-known inﬂammatory mediator that modulates pain and
immune processes2,3. It is produced by cyclooxygenase (COX) in
inﬂamed tissue. COX-2 is assumed to increase in inﬂammatory joint
disease including osteoarthritis (OA) and rheumatoid arthritis
(RA)4e6. COX-2 modulates inﬂammatory responses including che-
mokine release, adhesion molecule expression, plasma and cell
exudation, cytokine release and cellular proliferation7; thus COX-2
comprises all the feature of inﬂammation. Nonsteroidal anti-
inﬂammatory drugs (NSAIDs) target COX and inhibit PGE2
production. They are considered ﬁrst-line treatment for reduction
of pain and stiffness in arthritis8,9. However, side effects of NSAIDsublished by Elsevier Ltd. All rights reserved.
Table I
Primers of target genes
Target gene Size
(base pair)
COX-1 Forward TGCATGTGGCTGTGGATGTCATCAA 583
Reverse CACTAAGACAGACCCGTCATCTCCA
COX-2 Forward ACTCACTCAGTTTGTTGAGTCATTC 450
Reverse TTTGATTAGTACTGTAGGGTTAATG
TNF-a Forward GACCCTCACACTCAGATCAT 210
Reverse TTGAAGAGAACCTGGGAGTA
IL-1b Forward GCAACTGTTCCTGAACTC 382
Reverse CTCGGAGCCTGTAGTGCA
CCR5 Forward TTGCCCTGAGAAGAAAGGATG 336
Reverse ACAAAACTGTCTAGGTGCTCC
GAPDH Forward GTGAAGGTCGGTGTGAACGGATTT 553
Reverse CACAGTCTTCTGACTGGCAGTGAT
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apeutic ways with fewer side effects are needed.
In the adjuvant-induced mono-arthritis (AIA) model10,11,
complete Freund’s adjuvant (CFA) heat-killed Mycobacterium
butyricum or Mycobacterium tuberculosum has been injected into
the intra-articular space of the knee joint. Edema and pain are
produced within 12 h; cartilage destruction and bone erosion may
persist for several weeks12. In this arthritic model, higher level of
PGE2 (an index of COX-2 activity), thromboxane B2 (an index of
COX-1 activity), and proinﬂammatory cytokines TNF-a, IL-1b, and
IL-6 are seen in the serum and synovial ﬂuid13. Cytokine expression
in the inﬂamed synovial membrane of arthritis leads to formation
of osteoclasts14. These cells are primarily involved in the resorption
of mineralled cartilage and bone. Therefore, synovitis is not
considered as an incidental ﬁnding of OA, but plays a signiﬁcant
role in disease pathogenesis, and can therefore represent a target
for future treatment15.
Low intensity ultrasound (LIUS), an alternative source of
mechanical signals, has proven useful inmany diseases, particularly
in soft tissues disease involving cartilage or intervertebral disc16,17.
Recent studies report that LIUS is useful in promoting bone fracture
healing and tendon repair, and reducing postoperative pain and
swelling18. LIUS can be easily applied to targeted joints as local
physiotherapy18. In human OA patient, LIUS reduces joint pain
scores and also has chondroprotection19, which is observed in
various animal arthritic models20e22. LIUS regulates chondrocytes
and cartilage metabolism. In other reports LIUS was used for NSAID
phonophoresis to increase intradermal transport23 and uptake of
hyaluronan into the synovium in OA20. Previously, we report that
LIUS can help reducing the joint edema with reduction of PGE2 in
the synovial ﬂuid of surgical rabbit OA model. Despite these
promising ﬁndings, the effects of LIUS alone on the biological
activity of cytokines, COX enzymes and inﬂammation in arthritic
synovium have not been elucidated. Therefore, we hypothesized
that LIUS would affect arthritic synovium and might regulate
proinﬂammatory cytokines, COXs, iNOS and inﬁltration of immune
cells and subsequently affect AIA-induced arthritis.
Materials and methods
Induction of arthritis and ultrasound exposure
Inﬂammatory arthritis was induced in male Sparague-Dawley
rats (220e230 g; Samtako, Osan, Korea) with a modiﬁed method
described previously24. Brieﬂy, rats were anesthetized with
pentobarbital (60 mg/kg, Hanlim Pharm. Co., Seoul, Korea), and
150 mg of CFA (1mg/ml, Sigma, St. Louis, MO, USA)was injected into
the intra-articular space of the left knee joint. A sham-control
group was injected with 150 ml of saline. In the LIUS-treated group
(post-US), LIUS was applied on the ipsilateral left knee 1 day after
induction of arthritis. The ultrasound was applied by the thera-
peutic ultrasonic system (HNT medical, Seoul, Korea). LIUS was
generated in a continuous-wave mode at a frequency of 1 MHz and
intensity of 30, 100 and 200 mW/cm2. LIUS was applied for 10 min
everyday for 5 days.
Measurement of the knee circumference
To assess edema of the arthritic knee joint, rats were ﬁxed with
an acryl holder and the knee circumference of each rat was
measured using a ﬂexible tape measure. Eleven or 12 rats for each
group were examined (Sham; n ¼ 11, CFA; n ¼ 12, post-US; n ¼ 12)
and the ipsilateral knee circumferences were measured once in
everyday. The measurements were conducted for 5 days after
inﬂammation induction.Synovial membrane preparation
At 3 and 5 days after CFA injection, rats were anesthetized with
pentobarbital and transcardially perfused with steady ﬂow
(45 ml/min, 3 min) of 0.9% saline to remove blood from the tissue.
Then, the synovial membranes were collected from the knee joint
and immediately homogenized for mRNA extraction or stored
at 72C until used.
RNA isolation and semi-quantitative RT-PCR
To isolate total RNA, 3 days after CFA injection, synovial tissues
from seven rats for each group were collected and homogenized in
1 ml of Easy-Blue kit (Intron, Seongnam, Korea). Quality and purity
of the isolated RNA was checked by ND-1000 UV/Vis spectropho-
tometer (NanoDrop, Wilmington, DE, USA). One microgram of
total RNA was reverse transcribed to prepare cDNA using 0.5 mU
AMV reverse transcriptase (Roche, Indianapolis, IN, USA). PCR was
performed using 1 ml of cDNA from each sample. A TAKARA perfect
shot (TAKARA, Otsu, Japan) was used with a reaction mixture
containing 50 mM KCl, 10 mM TriseHCl (pH 9.0), 0.1% Triton X-100,
0.5 mMMgCl2, 200 mMdNTPs, 0.1 U/ml of Ex Taq DNA polymerase
and 1 mM each of forward and reverse primer. TNF-a and IL-1b
primer sequences were previously reported25. Table I described the
oligonucleotide primers.
Western blot analysis
Synovial tissues were collected at third (n ¼ 9 for each group)
and ﬁfth (n ¼ 12 for each group) day after CFA injection and
homogenized in homogenizing buffer [50 mM TriseCl (pH 7.4),
150 mM NaCl, 1% triton X-100, 0.1% sodium dodecyl sulfate (SDS),
1 mM MgCl2 and 0.5% sodium deoxychlorate] supplemented with
protein inhibitors. The supernatant was collected after centrifuga-
tion at 14,000 rpm for 15 min at 4C and its protein concentration
was then determined by BCA reagent (Thermo, Rockfore, IL, USA).
Fifty microgram of each protein samplewas denatured by boiling in
4 laemli buffer [51.25 mM TriseCl (pH 6.8), 10% glycerol, 2.5% SDS,
and 5% mercaptoethanol] and separated on a 10% SDS poly-
acrylamide gel. For immunoblotting, the proteins were transferred
onto a polyvinylidene ﬂuoride membrane (PVDF, Millipore, Bed-
ford, MA, USA)with a semi-dry transfer cell (BIO-RAD, Hercules, CA,
USA). The membranes were blocked 1 h in 20 mM TriseHCl (pH
7.6), containing 0.8% NaCl, 0.1% Tween20 (TBS-T) and 5% skim milk.
Then membranes were incubated with antibodies against COX-1
(1:500, Cayman, Ann Arbor, MI, USA), COX-2 (1:500, Cayman),
CD11b (1:1000, Abcam, San Diego, CA, USA) or b-actin (1:3000,
Sigma, St. Louis, MI, USA) for overnight. After washed membrane
Fig. 1. LIUS reduced knee circumference in CFA-induced arthritic rats.
CFA (150 mg) was injected into the left knee joint of each rat (CFA group) and after 24 h
LIUS was applied everyday for 4 days (post-US group). The sham group was injected
with vehicle. Knee circumference was measured each day after treatment. The data
represent observations from 9 to 11 animals per group (sham; n ¼ 9, CFA; n ¼ 11, post-
US; n ¼ 11) and displayed as means  95% conﬁdence intervals. *P < 0.05 vs sham and
#P < 0.05 vs CFA.
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peroxidase-conjugated secondary antibody (1:30,000, Jackson
Immunoresearch, Baltimore, PA, USA). For the quantiﬁcation of the
chemiluminescent signals, PVDF membranes were scanned with
a Fuji Film LAS-1000 system and analyzed using Multi Gauge
software (version 3.0).
Immunohistochemistry
The rats were anesthetized with sodium pentobarbital and
perfused transcardiallywith saline followedby4%paraformaldehyde
(PFA) in phosphate buffered saline (PBS). The synovium from the
knee joint was removed immediately and post-ﬁxed overnight in 4%
PFA and then cryoprotected with 30% sucrose in PBS for 48 h. Each
synovium was cut in 20 mm thick by a cryostat-microtome CM1900
(LEICA, Houston, TX, USA). The sectioned synovial tissue was
quenched with 0.3% H2O2 in PBS and then blocked with 5% normal
goat serum in PBS for 2 h. Later, blocked tissue was incubated with
rabbit anti-COX-1 (1:300, Cayman), anti-COX-2 (1:200, Cayman),
anti-CD11b (1:300, Abcam), anti-MPO (1:200, Dako, Glostrup, Den-
mark), and anti-Iba1 (1:300, Wako, Richmond, VA, USA) antibodies
followed by secondary antibody labeledwith Alexa Fluor 488 (1:300,
Invitrogen, Eugene, OR, USA). Nuclei were stained by Hoechst33258
and the tissue was mounted with VECTASHIELD (Vector Lab,
Burlingame, CA, USA). Images were acquired with a Zeiss LSM 710
confocal microscope (Carl Zeiss, Jena, Germany).
Statistical analysis
The data are expressed as the mean  95% conﬁdence interval.
Comparison of ultrasound effect between different groups was
done using one way analysis of variance (ANOVA) followed by the
Tukey test. The Spearman correlation test was performed for
correlation analysis in total animals including sham, inﬂammation
and post-US group. All analyses were performed using the
computer program SPSS 18.0 (SPSS Inc.) with a statistical signiﬁ-
cance of P < 0.05.
Results
Effect of LIUS on knee edema
The ipsilateral knee circumference in AIA rats began to increase
within 24 h, and edemawas maintained for 5 days. Treatment with
LIUS for 10 min was applied everyday beginning 24 h after arthritis
induction. Preliminary, we examined effect of various LIUS inten-
sities, 30, 100 and 200mW/cm2 (n¼ 5, each group) on knee edema.
LIUS reduced the knee circumference in a dose-dependent manner.
Five days after induction, the knee circumferences were reduced to
57.0 mm  2.48 (P ¼ 0.059 vs CFA group) in 30 mW/cm2,
56.4 mm  3.47 (P ¼ 0.017 vs CFA group) in 100 mW/cm2 and
55 mm  1.23 (P < 0.001 vs CFA group) in 200 mW/cm2 of LIUS,
while to 51.4 mm  1.05 in sham-control group and
60.47 mm  1.55 in only CFA group. In Fig. 1 (n ¼ 12), the effect of
LIUS with 200 mW/cm2 was shown. At 2 days after induction, knee
edemawas signiﬁcantly attenuated in LIUS-treated (post-US) group
compared with the untreated group (CFA). The difference between
the untreated group (CFA) and treated group increased over time.
At day 5, knee edema was reduced in the post-US group to that
controls (Fig. 1).
Effect of LIUS on inﬂammatory mediators
To evaluate the anti-inﬂammatory effect of LIUS stimulation on
arthritic joint, gene and protein levels of the inﬂammatorymediators COX-1, COX-2, IL-1b, TNF-a and iNOS were measured in
the synovium. COX-1, COX-2 and IL-1b genes were highly expressed
in the inﬂammatory synovium 3 days after AIA induction; however
TNF-a expression remained at the basal level. The administration of
LIUS signiﬁcantly reduced the levels of COX-2 (P ¼ 0.008) and IL-1b
(P ¼ 0.026) [Fig. 2(A)]. The decrease of COX-1 mRNA expression by
LIUS was not statistically signiﬁcant, however the expression of
COX-2 and IL-1b was inhibited by LIUS and positively correlated
with knee circumference. Speciﬁcally COX-2 (r ¼ 0.803, P < 0.001)
showed very strong correlation [Fig. 2(B)].
Protein levels of inﬂammatory molecules were also analyzed
in the synovium. AIA induction enhanced not only expression of
COX-1, COX-2 and iNOS, the synthesizing enzymes for inﬂam-
matory mediators including PGs and NO, but also expression of
CD11b, which is a widely used immune cell marker for neutro-
phils, basophils, monocytes and macrophage. Increased levels of
these proteins were present on both day 3 [Fig. 3(A)] and day 5
[Fig. 3(B)]. Coincident with the reduction in edema, LIUS reduced
expression of COX-1, COX-2, iNOS and CD11b [Fig. 3(A and B)]. On
day 5 LIUS signiﬁcantly decreased COX-2 (P ¼ 0.001) and iNOS
(P ¼ 0.007), but not COX-1 (P ¼ 0.36). In contrast, on day 5, LIUS
stimulation signiﬁcantly decreased COX-1 (P ¼ 0.002), but not
COX-2 (P ¼ 0.07) and iNOS (P ¼ 0.15). CD11b was signiﬁcantly
reduced by LIUS on both day 3 (P ¼ 0.04) and day 5 (P ¼ 0.01). To
demonstrate that the anti-edema effect of LIUS was achieved
through regulation of these inﬂammatory molecules, we analyzed
the correlation between knee circumference and the relative
expression levels of inﬂammatory molecules among three groups.
Expression of inﬂammatory molecules including COX-1, COX-2,
iNOS and CD11b showed a strong correlation with knee circum-
ference (Table II). This data suggests that the development of
edema coincides with up-regulation of inﬂammatory mediators.
The ﬁrst step of the inﬂammatory process correlates with
immune cell inﬁltration. The degree of immune cell inﬁltration is
represented by CD11b expression. The expression of enzymes
responsible for production of PGs and NO correlated strongly
with expression of CD11b (Table III) on day 3. These data
suggest that PGs and NO production is involved in immune cell
inﬁltration.
Fig. 2. CFA induced mRNA expression of inﬂammatory mediators in synovial membrane.
(A) Expression of inﬂammatory mediators including COX-1, COX-2, TNF-a and IL-1b mRNA was measured in the synovial membrane 3 days after CFA injection. The mRNA levels
were normalized to GAPDH (n ¼ 7) and represented relative to control. Except TNF-a, expression of all inﬂammatory genes was increased in arthritic synovial membranes, which
were signiﬁcantly reduced by LIUS. (B) Correlation between ipsilateral knee circumference and COX-1, COX-2, IL-1b and TNF-a mRNA relative expression in CFA-induced arthritic
synovium. Statistical correlation analysis was performed using Spearman correlation analyses. Data are displayed as means  95% conﬁdence intervals. *P < 0.05 vs sham and
#P < 0.05 vs CFA.
Fig. 3. LIUS attenuated the expression of inﬂammatory mediators in synovial membrane.
Western blot analysis was performed with the tissue collected 3 days (A) and 5 days (B) after CFA injection. Blots are representative immunoblots of sham, CFA and post-US group.
The relative integrated density values of COX-1, COX-2, iNOS and CD11b protein levels were normalized to b-actin (Day 3; n ¼ 9, Day 5; n ¼ 12 for each group). Data are displayed as
means  95% conﬁdence intervals. *P < 0.05 vs sham and #P < 0.05 vs CFA.
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Table II
Correlation with knee circumference
Relative protein expression Day 3 Day 5
Coefﬁcient P-value Coefﬁcient P-value
COX-1 0.639 0.001 0.051 0.761
COX-2 0.808 <0.001 0.483 0.002
iNOS 0.792 <0.001 0.546 0.003
CD11b 0.790 <0.001 0.693 0.001
Table III
Correlation with CD11b relative expression
Relative protein expression Day 3 Day 5
Coefﬁcient P-value Coefﬁcient P-value
COX-1 0.598 0.003 0.108 0.669
COX-2 0.610 0.002 0.257 0.303
iNOS 0.867 <0.001 0.876 <0.001
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Expression of CCR5, an important chemotactic factor in arthritis,
was studied. To evaluate the effect of LIUS stimulation on chemo-
taxis into synovial tissue, the level of CCR5 gene in the synovium
was measured. CCR5 was highly expressed in the inﬂammatory
synovium 3 days after AIA induction, and administration of LIUS
signiﬁcantly reduced this expression (P¼ 0.006) (Fig. 4). Expression
of CCR5 was inhibited by LIUS and positively correlated with knee
circumference (r ¼ 0.626, P ¼ 0.004) (Fig. 5).
Effect of LIUS on immune cells recruitment
We immunohistochemically examined leukocyte inﬁltration in
arthritic synovium and the effect of LIUS on leukocyte migration. To
deﬁne the inﬁltrating cells, myeloperoxidase (MPO) and ionized
calcium binding adaptor molecule 1 (Iba1) antibody were used. The
MPO-positive cells represent neutrophils and Iba1-positive cells
represent monocytes and macrophages. In the CFA-induced
arthritic synovium, the numbers of CD11b-positive cells were
increased. All CD11b-positive cells also expressed COX-1 and COX-2
(data not shown). Generally, neutrophils are the ﬁrst immune cell
to inﬁltrate the site of inﬂammation, where they promote the
release of inﬂammatory mediators and the chemotaxis of other
immune cells. Macrophages are recruited after neutrophils inﬁl-
tration. AIA induction profoundly increased neutrophil and
macrophage inﬁltration in the synovium. On day 3, the arthriticFig. 4. CFA induced CCR5 mRNA expression of inﬂammatory mediators in synovial mem
(A) Expression of chemoattractant chemokine receptor CCR5 mRNA was measured in the s
GAPDH (n ¼ 7) and reported relative to the control. (C) Correlation between ipsilateral knee
mRNA levels were normalized to GAPDH (n ¼ 7). Statistical correlation analysis was perf
conﬁdence intervals. *P < 0.05 vs sham and #P < 0.05 vs CFA.synovium was swollen and ﬁlled with MPO-positive cells in the
core surrounded by Iba1-positive cells. On day 5, the MPO-positive
cells disappeared and the Iba1-positive cells populated the core. In
LIUS-treated group, the MPO-positive core was not prominent and
neutrophil inﬁltration was signiﬁcantly decreased on day 3
compared to the non-treated group. Therefore, the anti-
inﬂammatory effect of LIUS might be due to decreased inﬂamma-
tory cell inﬁltration.Discussion
In the present study, AIA produced profound edema of the
injected knee, increased expression of inﬂammatory mediator
genes including COX-2, iNOS, IL-1b and CCR5, and promoted
inﬂammatory cell inﬁltration in the synovium. LIUS induced
reduction in knee swelling and inﬂammatory markers in the
synovium apparently via a reduction in inﬂammatory cell inﬁltrate.
Ultrasound is used as an alternative treatment to conventional
medical therapy. As discussed above, it has been applied in many
different ﬁelds16,18,22,26. The beneﬁcial biological effects of ultra-
sound have been applied to tissue regeneration, cancer treatment,
and immune and vascular stimulation26. In randomized, placebo-
controlled, and double-blind study, LIUS can be efﬁcacious for
decreasing pain and may improve physical function in human knee
OA19,27. In animal OA model, LIUS increases the articular cartilage
type II collagen, thereby exhibiting chondroprotective action22.
Ultrasound induced in aggrecan gene expression and chondroitin
sulfate synthesis in chondrocytes originated from rat28, rabbit29,
and also human OA patient30. Specially, LUIS also prevents the
spontaneous articular degeneration in guinea pig model, and
reduced TGF-b1 production considered as acute repair response21.
Therefore, the chondroprotective effect of LIUS is not determined
by whether active repair or reduced cartilage degeneration. In our
study, LUIS can modulate inﬂammatory process in the synovium,
thereby the protective effect of LUIS on OA cartilages can be
explained. Furthermore, regulation of synovial inﬂammation can be
an important target for treatment of OA.
We demonstrated the protective effect of LIUS on CFA-induced
edema with 0.2 W/cm2 intensity, 1 MHz for every 5 days. In CFA-
induced arthritis model, edema began several hours after injec-
tion and approached a peak 2e3 days, and began to subside after
5 days. Therefore, we treated LIUS after 1 day and then every 5 days.
This ultrasonic energy can be divided into two categories: high-
intensity ultrasound with peak intensities from 5000 to
15,000 W/cm2, and LIUS with intensities of 0.5e3000 W/cm2 17.
US is widely used as an imaging modality at intensity ofbrane.
ynovial membrane 3 days after CFA injection. (B) The mRNA level was normalized to
circumference and CCR5 mRNA relative expression in CFA-induced arthritic synovium.
ormed by using Spearman correlation analyses. Data are displayed as means  95%
Fig. 5. Immunohistochemical analysis of inﬂamed synovium.
The localization of MPO and Iba1 on days 3 and 5. (A) At days 3 and 5 after CFA injection, sections were labeled with MPO and Iba1 antibodies and visualized with Alexa Fluor 488
Dye conjugated secondary antibodies. Nuclei were stained with Hoechst. Scale bars ¼ 500 mm. (B) Higher magniﬁcation of box in (A). Scale bars ¼ 100 mm. The MPOþ neutrophils
(green) were inﬁltrating the inﬂamed synovium on day 3 and disappeared on day 5. Iba1þ macrophages/monocytes were located around the MPO core on day 3. Almost all cells of
the MPOþ core were replaced by highly activated macrophages on day 5. LIUS attenuated neutrophil and macrophage inﬁltration on both day 3 and 5. Images were acquired with
a Zeiss LSM 710 confocal microscope (Carl Zeiss).
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0.2e100 W/cm cm2, and as improving bone healing at <0.1 W/cm2
17. In the present study, LIUS against CFA-induced edema in rats has
been shown from 0.03 W/cm2 for 10 min 5 days after application,
and LIUS with intensity of 0.2 W/cm2 for 10 min re-showed
reducing edema 1 day after application.
Proinﬂammatory cytokines, including IL-1b and TNF-a, play
a key role in the regulation of inﬂammation. However, these two
cytokines are thought to act independently in acute arthritismodels. IL-1b is the most important cytokine in the pathogenic
progress of arthritis. It induces the production of matrix metal-
loproteinase (MMP) and PGE2 through increasing COX-2 expres-
sion31,32. Kuiper et al. reported the differential kinetics of TNF-a and
IL-1b production. In their experiments TNF-a peaked earlier than
IL-1b, and was not involved in cell inﬂux or proteoglycan metabo-
lism33. IL-1b plays a dominant role in inﬂammatory cell inﬁltration
and cartilage destruction, whereas TNF-a regulates joint
swelling33,34. In their model TNF-a was not involved in rigorous
J.-I. Chung et al. / Osteoarthritis and Cartilage 20 (2012) 314e322320immune processes, a ﬁnding conﬁrmed by our study. TNF-a is
expressed in the lining of the synovial membrane at the time of
arthritis onset; IL-1b is also detected but at a slightly later stage of
the disease35. In our study, there was little change in TNF-
a expression on day 3, while IL-1b expression was increased.
However, the increased knee circumference correlated closely with
IL-1b level and with COX expression, but not TNF-a.
COX-2 is induced and activated by inﬂammation to produce
PGE2, which modulates pain, swelling and cytokine release. COX-2
is highly expressed in both OA and RA patients and in animal
models5,36,37. PGE2 promotes angiogenesis and arthritic tissue
degradation via inhibition of collagen synthesis, increased MMP
release, and enhanced chondrocyte apoptosis38. The other impor-
tant inﬂammatory marker, iNOS, is induced by inﬂammatory
stimuli. NO released from iNOS is a readily diffusible and highly
reactive. NO exhibits both pro- and anti-inﬂammatory properties39.
Our data revealed that both COX-2 and iNOS mRNA and protein
level increased signiﬁcantly on day 3 and day 5, in AIA synovium.
The expression of COX-2 and iNOS was attenuated by LIUS treat-
ment. As reported earlier, COX-2 inhibition is considered a primary
therapeutic approach for relief of mild to moderate pain. In our
study, COX-2 expression is highly correlated with knee edema.
NSAIDs, which inhibit COX, are used clinically based on their anti-
inﬂammatory and analgesic properties. The ﬁrst generation of
NSAIDs inhibits both COX isoforms and carries a risk of gastric ulcer.
Adverse gastrointestinal toxicity is attributed to the inhibition of
gastroprotective PGs, which are mainly produced by the homeo-
static COX-1 pathway40. Second generation NSAIDs, the selective
COX-2 inhibitors such as celecoxib or rofecoxib, have the advantage
of reduced gastrointestinal toxicity; however, cardiovascular
toxicity has been reported with these drugs. Based on this data and
results of our study, LIUS stimulation may represent an alternative
treatment to reduce COX-2 and iNOS expression, especially in the
early stage of arthritic joint.
Cellular inﬁltration is one pathologic process involved in
arthritis; this includes an increase in tissue macrophages and
abnormal hypertrophy of the synovial membrane41. In the arthritic
synovial membrane, increased cellularity is obvious, which repre-
sents cellular migration from circulating blood35. In our model,
CD11b-positive cells inﬁltrated the arthritic synovium and the
potent chemotaxic chemokine receptor CCR5 was also increased.
CCR5 is the natural receptor for the ligands CCL3 (macrophage
inﬂammatory protein 1a, MIP-1a), CCL4 (MIP-1b), and CCL5
(RANTES), all of which contribute to chemotactic activity in the
synovial ﬂuid of patients with RA. The CCR5 density on Tcell surface
is constant over time for a given individual but varies drastically
from one individual to another; this may represent a factor deter-
mining the intensity of joint inﬂammation in the course of RA42.
Leukocytes, including neutrophils, macrophages and ﬁbroblasts,
are the primary source of cytokines. The synovial macrophages and
ﬁbroblasts produce a plethora of proinﬂammatory cytokines,
including ILs, TNFs and GM-CSF and other cytokines and chemo-
kines43. Activated neutrophils are reportedly a source of leukotriens
and PGs, which synthesize IL-1, IL-1RA, IL-6, IL-12 and TNF-a. These
cytokines can subsequently activate neutrophils and other cells44.
In our study, these inﬂammatory mediators correlated with CD11b
and also knee circumference. The source of these proinﬂammatory
mediators appears to be inﬁltrating inﬂammatory cells, and the
level of cellular inﬁltration strongly correlated with inﬂammatory
mediator production.
Granulocytes, including neutrophils, eosinophils and basophils,
are innate immune cells containing specialized granules; they
provide the ﬁrst line of immune defense. Neutrophils in particular
predominate in early cellular inﬁltrate into the inﬂammatory sites
and act via phagocytosis. Monocytes and macrophages destroymicrobes later in the innate immune response. In the present study,
MPO-positive neutrophils and Iba1-positive monocytes/macro-
phages were present in the inﬂamed synovium. MPO is the most
prevalent protein in mature neutrophils and is a speciﬁc enzyme
responsible for the production of highly reactive hypochlorous acid,
chloride gas and chlorinated peptides, which act as a cytotoxic triad
resulting cell death.MPO binds to themacrophagemannose receptor
(MMR) and induces secretion of proinﬂammatory cytokines45. MPO
may be present in the synovial ﬂuid of patients of OA 46 and RA47. In
the present study, MPO activity in CFA-induced synovitis peaked
3 days after induction, but was almost completely resolved by
day 5. This suggested that neutrophils, which survive 2e3 days,
are no longer present. LIUS decreased the MPO activity in the
arthritic synovium.
Iba1, ionized calcium binding adaptor molecule 1, is a calcium
binding protein whose expression is restricting to macrophage/
microglia48. Iba1 is localized in the cytoplasm and nucleus,
however in the activated state Iba1 colocalized with F-action in
membrane rufﬂes during phagocytosis49. In this study we
demonstrated Iba1 immunoreactivity in the synovium. The
immunoreactivity of MPO and Iba1 was not overlapped. In the
sham control, Iba1 stained a few spindle-shaped cells; however,
CFA-induced synovitis showed increased Iba1 staining, which
represented membrane rufﬂing and increased phagocytosis. At day
3, MPO-positive neutrophils were present in the core and Iba1-
positive cells surrounded the core. Later, MPO-positive cells
nearly disappeared with only a few positive cells remaining. The
core was populated by Iba1-positive cells after 5 days. Therefore,
neutrophils ﬁrst inﬁltrate the inﬂamed synovium and release MPO
which induces either a cytotoxic effect on infected cells or proin-
ﬂammatory cytokine secretion by macrophages. Activated macro-
phages then enhance their phagocytic function by increasing Iba1
expression; this is followed by resolution of the inﬂammatory
process. LIUS treatment markedly reduced leukocytes inﬁltration in
the synovium and also attenuated hyperplasia. Therefore, the anti-
inﬂammatory effect of LIUS is closely related to modulation of
inﬁltrating inﬂammatory cells.
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